The Evolving Role of Biomarkers in Oncology
This CME certified activity is jointly provided by:
Harborside Medical Education
Harborside Medical Education (HSME), a division of Harborside, is committed to advancing care for people with cancer and improving patient outcomes through professional continuing education (CE) activities in oncology that address practice gaps and promote change in learners’ knowledge, competence and performance in both community and academic practice settings.
Release date: December 21, 2018
Expiration date: December 21, 2019
Annenberg Center for Health Sciences at Eisenhower
39000 Bob Hope Drive, Dinah Shore Bldg.
Rancho Mirage, CA 92270
Estimated time to complete activity: 0.25 hour
The ASCO Post
94 North Woodhull Road
Huntington, NY 11743
This activity is supported by educational grants from Bristol-Myers Squibb and Lilly USA, LLC.
The activity’s target audience will consist of medical and hematologic oncologists, physician assistants (PAs), and other clinicians who care for people with cancer.
After completing this educational activity, participants should be able to:
- Apply current recommendations regarding available biomarker tests to patients who may be candidates for checkpoint inhibitor therapy
- Explain the clinical significance of emerging data regarding biomarker testing
- Identify patients who are likely to benefit from checkpoint inhibitor therapy
Physicians. This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Annenberg Center for Health Sciences at Eisenhower and HSME. The Annenberg Center is accredited by the ACCME to provide continuing medical education for physicians.
The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
PAs may claim a maximum of 0.25 Category 1 credits for completing this activity. The National Commission on Certification of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.
All individuals in positions to control the content of this program (eg, planners, faculty, content reviewers) are expected to disclose all financial relationships with commercial interests that may have a direct bearing on the subject matter of this CME activity. The Annenberg Center for Health Sciences at Eisenhower has identified and resolved all conflicts of interest in accordance with the Annenberg Center for Health Sciences at Eisenhower policies and procedures. Participants have the responsibility to assess the impact (if any) of the disclosed information on the educational value of the activity.
Hossein Borghaei, DO, MS: Advisory Board and Consulting: BMS, Lilly, Genentech, AbbVie, Amgen, AstraZeneca, EMD-Serono, Genmab, Regeneron, Merck, Axiom, Novartis, Celgene, BioNTech, Cantargia AB
Vamsidhar Velcheti, MD: Advisory Board and Consulting: Merck, Bristol-Myers Squibb, Genentech, Celgene, Novartis, Amgen, AstraZeneca, Foundation Medicine, Takeda Oncology, Reddy Labs
Annenberg Center for Health Sciences at Eisenhower
Charles Willis, Director, Continuing Education, consults for Pfizer Inc.; all other staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.
Harborside and HSME staff have no potential conflicts of interest to disclose.
This activity has been designed to provide CME that is focused on specific objectives. In selecting educational activities, clinicians should pay special attention to the relevance of those objectives and the application to their particular needs. The intent of all Annenberg Center for Health Sciences at Eisenhower educational opportunities is to provide learning that will improve patient care. Clinicians are encouraged to reflect on this activity and its applicability to their own patient population. The opinions expressed in this activity are those of the faculty and reviewers and do not represent an endorsement by Annenberg Center for Health Sciences at Eisenhower of any specific therapeutics or approaches to diagnosis or patient management.
This educational activity may contain discussion of published as well as investigational uses of agents that are not approved by the U.S. Food and Drug Administration. For additional information about approved uses, including approved indications, contraindications, and warnings, please refer to the prescribing information for each product.
How to Earn Credit
Learners must complete the learning assessment and evaluation.
Statement of Credit: Participants who successfully complete this activity (including scoring of a minimum of 70% on the learning assessment) and complete and submit the evaluation form will be able to download a statement of credit.
- 0.25 AMA PRA Category 1 Credit(s)™
- 0.25 Attendance